Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
Revive Therapeutics (OTCQB: RVVTF) announced the publication of research demonstrating psilocybin's potential as a novel therapeutic approach for stroke treatment. The study, published in BMC Neuroscience, showed that psilocybin reduced brain infarction and improved locomotor behavior in stroke rats by regulating BDNF expression. The research supports the company's PCT application for using psilocybin to treat neurological brain injury and migraines, acquired from PharmaTher Holdings in February 2021. The company is developing novel delivery methods, including an oral thin-film and microneedle patch for psilocybin administration.
Revive Therapeutics (OTCQB: RVVTF) ha annunciato la pubblicazione di una ricerca che dimostra il potenziale della psilocibina come approccio terapeutico innovativo per il trattamento dell'ictus. Lo studio, pubblicato su BMC Neuroscience, ha mostrato che la psilocibina ha ridotto l'infrazione cerebrale e migliorato il comportamento locomotorio in ratti colpiti da ictus regolando l'espressione del BDNF. La ricerca supporta la domanda di PCT dell'azienda per utilizzare la psilocibina nel trattamento del danno neurologico cerebrale e dell'emicrania, acquisita da PharmaTher Holdings nel febbraio 2021. L'azienda sta sviluppando nuovi metodi di somministrazione, inclusi un film sottile orale e un cerotto con microaghi per la somministrazione della psilocibina.
Revive Therapeutics (OTCQB: RVVTF) anunció la publicación de una investigación que demuestra el potencial de la psilocibina como un enfoque terapéutico novedoso para el tratamiento del accidente cerebrovascular. El estudio, publicado en BMC Neuroscience, mostró que la psilocibina redujo la infacción cerebral y mejoró el comportamiento locomotor en ratas con accidente cerebrovascular regulando la expresión de BDNF. La investigación respalda la solicitud de PCT de la empresa para utilizar psilocibina en el tratamiento de lesiones neurológicas cerebrales y migrañas, adquirida de PharmaTher Holdings en febrero de 2021. La empresa está desarrollando nuevos métodos de entrega, incluidos un film oral delgado y un parche de microagujas para la administración de psilocibina.
Revive Therapeutics (OTCQB: RVVTF)는 뇌졸중 치료를 위한 새로운 치료 접근법으로서의 실로시빈의 잠재력을 입증하는 연구 발표를 알렸습니다. BMC Neuroscience에 발표된 이 연구는 실로시빈이 뇌 경색을 줄이고 뇌졸중 쥐의 운동 행동을 개선했으며, BDNF 발현을 조절함으로써 이루어졌음을 보여주었습니다. 이 연구는 회복적 뇌 손상 및 편두통 치료를 위한 실로시빈 사용에 대한 회사의 PCT 신청을 뒷받침합니다. 이 회사는 실로시빈 투여를 위한 경구용 박막 및 미세 침 패치 등 새로운 전달 방법을 개발하고 있습니다.
Revive Therapeutics (OTCQB: RVVTF) a annoncé la publication d'une recherche démontrant le potentiel de la psilocybine comme approche thérapeutique novatrice pour le traitement des AVC. L'étude, publiée dans BMC Neuroscience, a montré que la psilocybine réduisait l'infarctus cérébral et améliorait le comportement locomoteur chez des rats victimes d'AVC en régulant l'expression du BDNF. La recherche soutient la demande de PCT de l'entreprise pour utiliser la psilocybine dans le traitement des lésions cérébrales neurologiques et des migraines, acquise auprès de PharmaTher Holdings en février 2021. L'entreprise développe de nouvelles méthodes d'administration, notamment un film oral mince et un patch à micro-aiguilles pour la délivrance de psilocybine.
Revive Therapeutics (OTCQB: RVVTF) hat die Veröffentlichung einer Forschung bekannt gegeben, die das Potenzial von Psilocybin als neuartigen therapeutischen Ansatz zur Behandlung von Schlaganfällen zeigt. Die Studie, die in BMC Neuroscience veröffentlicht wurde, zeigte, dass Psilocybin die Hirninfarkte reduzierte und das Lokomotorverhalten bei Schlaganfallratten durch Regulierung der BDNF-Expression verbesserte. Die Forschung unterstützt den PCT-Antrag des Unternehmens zur Verwendung von Psilocybin zur Behandlung von neurologischen Hirnverletzungen und Migräne, die im Februar 2021 von PharmaTher Holdings übernommen wurden. Das Unternehmen entwickelt neuartige Verabreichungsmethoden, einschließlich eines oralen Dünnfilms und eines Mikronadel-Patches zur Verabreichung von Psilocybin.
- Research demonstrates psilocybin's efficacy in reducing brain infarction in stroke models
- Company owns PCT application for psilocybin treatment of neurological brain injury
- Development of innovative drug delivery systems (oral thin-film and microneedle patch)
- None.
TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, medical countermeasures and rare disorders, today announced the publication of a scientific article demonstrating the potential of psilocybin as a novel therapeutic approach in stroke. The publication, entitled, “Neuroprotective effects of psilocybin in a rat model of stroke,” is published in BMC Neuroscience and is available here.
The research and intellectual property were part of the acquisition of assets from PharmaTher Holdings Ltd (CSE: PHRM) (OTCQB: PHRRF) in February 2021. The research study supported the Company’s PCT application (PCT/CA2021/050360), titled, “Use of Psilocybin in the Treatment of Neurological Brain Injury and Migraines.” The objective of the research study was to determine the protective effect of psilocybin in cellular and animal models of stroke. In the study, psilocybin reduced brain infarction and improved locomotor behavior in stroke rats; the protective mechanisms involve regulating BDNF expression.
Michael Frank, CEO of Revive, commented: “We have a diverse psilocybin-based pharmaceutical program that has been quietly moving forward with the aim of treating neurological, mental health and substance abuse disorders. The publication of the research study demonstrating psilocybin’s therapeutic potential in the treatment of stroke, which is often associated with subsequent depression, validates our strategic initiative to focus on evaluating psilocybin in clinical studies and novel delivery methods, such as our in-development psilocybin oral thin-film and microneedle patch.”
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin-based therapeutics through various programs. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the year ended June 30, 2024 ("MD&A"), dated October 25, 2024, which is available on the Company's profile at www.sedarplus.ca.
FAQ
What are the key findings of Revive Therapeutics' (RVVTF) psilocybin stroke study?
What delivery methods is Revive Therapeutics (RVVTF) developing for psilocybin?
When did Revive Therapeutics (RVVTF) acquire the psilocybin research assets?
